Clinical Trial

Characterization of Exosomes Platelets-released

Study acronym: EXOPLT
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 12, 2024 (before its estimated July 7, 2026 completion). Its status may not reflect the trial's current state.
Summary
Extracellular vesicles (EVs) play a key role in cell-to-cell communication. They are small vesicles that contain rich molecular cargo. Recently, they have been proposed as biomarkers for clinical diagnostics. EVs include three classes: small EVs (exosomes), large EVs (microparticles), and apoptotic bodies. Platelet-derived EVs (PEVs) are the most abundant class in human blood and can actively participate in numerous physiological and pathological processes. The information about the role of platelet exosomes in cardiovascular disease and the effect of antiplatelet agents on their release and content is very limited.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-01.
Trial Details
NCT Number NCT06298682
Lead Sponsor Centro Cardiologico Monzino
Collaborators: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Conditions Platelet Thrombus
Enrollment 175 participants
Start Date 2021-07-08
Primary Completion 2026-07-07 (estimated)
Study Completion 2027-07-07 (estimated)
Updated on ClinicalTrials.gov 2024-03-12